Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of ABT-SLV187 in Advanced Parkinson's Disease
jRCT2080222432Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of levodopa + carbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability of long-term ABT-SLV187 treatment and Efficacy of ABT-SLV187 on motor complications.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080222432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222432.